Overview
IBRX market data
Price History
IBRX price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$0.38 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.07 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -598.6% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $1.95 – $12.43 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $8.1B · P/B 3.09 · P/S 48.94.
Company News
ImmunityBio shares are trading lower after the company reported a wider GAAP net loss for the second quarter reflecting a sharp increase in expenses.Benzinga · Aug 4, 2026, 3:04 PM
ImmunityBio Q2 Adj. EPS $(0.08) Beats $(0.09) Estimate, Sales $51.240M Beat $49.700M EstimateBenzinga · Aug 4, 2026, 11:41 AM
8-K filing — ImmunityBio, Inc. (IBRX)SEC EDGAR · Aug 4, 2026, 11:36 AM
ImmunityBio shares are trading higher after the company announced that the Emirates Drug Establishment of the United Arab Emirates has granted Marketing Authorization for ANKTIVA across two indications.Benzinga · Jul 30, 2026, 6:49 PM
ImmunityBio Achieves World's Broadest Bladder Cancer Approval as UAE Green Lights Lead DrugBenzinga · Jul 30, 2026, 5:19 PM
Reported Earlier, ImmunityBio's ANKTIVA Wins UAE Nod For NSCLC After QUILT-3.055 Trial Showed 14.6-Month Median Overall Survival In Checkpoint-Refractory PatientsBenzinga · Jul 30, 2026, 8:14 AM
Squeeze Watch: 10 Stocks Bears Love to Hate Most Right NowBenzinga · Jul 13, 2026, 6:29 PM
Jim Cramer Calls CAVA 'Tasty, Clean, Fun,' Says Make This Biotech 'Your Speculation'Benzinga · Jun 17, 2026, 11:55 AM
HC Wainwright & Co. Reiterates Buy on ImmunityBio, Maintains $15 Price TargetBenzinga · Jun 2, 2026, 10:37 AM
ImmunityBio Presents Data At American Society Of Clinical Oncology Annual Meeting About Its Phase 3 Studies In Advanced Non-Small Cell Lung CancerBenzinga · Jun 1, 2026, 5:55 PM